BrightEdge

Auron Therapeutics is a biotechnology company focused on cancer therapy development that seeks to change the paradigm from tumor cell killing to differentiation therapy, aiming to transform malignant cells into normal functioning cells by reactivating endogenous cellular programs. The company uses platforms that integrate large-omic datasets and miniaturized high-throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. This approach is designed to advance therapeutic candidates for cancer across areas of unmet medical need and to support the development of transformative medicines. Auron Therapeutics was founded in 2018 and is based in Wellesley, Massachusetts.

Clasp Therapeutics develops precision oncology platforms to identify neoantigens from driver mutations in hard-to-treat cancers. Its technology enables the creation of targeted therapies that selectively bind to HLA-presented peptides, allowing for precise destruction of cancer cells across various tumor types.

Modifi Bio develops oncology therapeutics based on direct DNA modification. The company pursues a platform that modifies tumor DNA to render cancer cells irreparable while preserving healthy cells, aiming to disrupt conventional oncology drug development.

Thatch is a digital platform designed to streamline employee healthcare management for businesses. It offers an AI-driven assistant, ThatchBot, which provides round-the-clock support for employees' healthcare queries and expense tracking. The platform enables companies to set personalized healthcare budgets for each employee, fostering tailored healthcare experiences and efficient benefits navigation.

Thatch is a digital platform designed to streamline employee healthcare management for businesses. It offers an AI-driven assistant, ThatchBot, which provides round-the-clock support for employees' healthcare queries and expense tracking. The platform enables companies to set personalized healthcare budgets for each employee, fostering tailored healthcare experiences and efficient benefits navigation.

Paradigm is rebuilding the clinical research ecosystem by developing a platform that allows all patients equitable access to trials while improving trial efficiency and lowering barriers to participation for healthcare providers. It is an innovative company that is dedicated to transforming the clinical research ecosystem. Their mission is to create a more accessible and equitable healthcare system by developing a platform that enables patients from diverse backgrounds to participate in clinical trials. Clinical trials are essential for testing and developing new drugs, therapies, and medical devices, but historically, they have been plagued by inefficiencies, barriers to access, and inequities in patient representation. Paradigm aims to solve these challenges by creating a platform that uses technology and data-driven insights to streamline the clinical trial process, making it more efficient, cost-effective, and inclusive. The Paradigm platform is designed to facilitate seamless communication and collaboration among all stakeholders involved in clinical research, including patients, healthcare providers, pharmaceutical companies, and regulatory agencies. By leveraging technology such as AI, machine learning, and predictive analytics, Paradigm can identify and match eligible patients to clinical trials, streamline the recruitment and enrollment process, and provide real-time data insights to all stakeholders. Overall, Paradigm's innovative approach to clinical research has the potential to revolutionize the healthcare industry by improving patient outcomes, reducing healthcare costs, and accelerating the development of new treatments and therapies.

Alpheus Medical develops a sonodynamic therapy platform for solid tumors, combining a drug with a device activated by ultrasound to deliver targeted treatment for recurrent glioblastoma multiforme and other cancers. The non-invasive outpatient approach aims to avoid imaging and hospital admission while concentrating therapy on malignant tissues.

Vincere Health Inc. is a health technology company based in Allston, Massachusetts, founded in 2019 at the Harvard Innovation Labs. The company specializes in developing a health engagement platform aimed at assisting users in quitting smoking and making healthier choices. Its application combines behavioral nudges, evidence-based interventions, and personalized coaching, allowing users to set individual goals and monitor their progress. Users engage with the platform by using an attachable breathalyzer device to verify adherence to their smoking reduction goals. The application incentivizes users with periodic financial rewards for reducing their smoking and achieving cessation. By leveraging real-time health data and intelligent incentives, Vincere Health addresses significant healthcare challenges, particularly in smoking cessation and chronic disease management.

Meliora Therapeutics is a biotech startup focused on developing innovative cancer therapies by leveraging a machine learning-driven platform. The company aims to identify the true mechanisms of action (MOA) of oncology medications through its proprietary prediction atlas, which maps drug mechanisms. This approach streamlines the drug development process by eliminating a significant and costly phase, thereby allowing researchers to advance their work more efficiently. By focusing on the precise actions of molecules of interest, Meliora Therapeutics seeks to enhance the effectiveness of cancer treatments and contribute to life-saving medical advancements in oncology.

Naveris is a biotechnology company developing highly sensitive blood tests for cancer detection, monitoring, and recurrence tracking. Its NavDx blood test detects cancer by quantifying tumor-derived DNA fragments in the blood, enabling early diagnosis—including in asymptomatic individuals—real-time monitoring of treatment response, and surveillance for recurrence. The company combines a 3D biomimetic technology that replicates tissue and tumor complexity ex vivo to support oncology research and precision medicine, advancing clinical trial design and matching therapies to patients. Naveris was founded in 2017 and is headquartered in Waltham, Massachusetts.

Auron Therapeutics is a biotechnology company focused on cancer therapy development that seeks to change the paradigm from tumor cell killing to differentiation therapy, aiming to transform malignant cells into normal functioning cells by reactivating endogenous cellular programs. The company uses platforms that integrate large-omic datasets and miniaturized high-throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. This approach is designed to advance therapeutic candidates for cancer across areas of unmet medical need and to support the development of transformative medicines. Auron Therapeutics was founded in 2018 and is based in Wellesley, Massachusetts.

Persephone Biome, Inc. is a San Diego-based company focused on researching and developing products and therapies that modify gut microbial metabolism, particularly in relation to cancer treatment. Established in 2017, the company is creating innovative solutions aimed at enhancing the efficacy of oncology drugs by retuning the gut microbiome. This includes the development of a pill containing beneficial gut bacteria. In addition to its therapeutics, Persephone Biome aims to offer nutritional products that support the human gut microbiome, producing functional foods and beverages that cater to the growing consumer demand for health-oriented products. The company has plans to enter clinical trials to further advance its initiatives in the field of microbiome-directed therapies.

CellCentric Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer therapeutics. Established in 2003, the company specializes in small-molecule inhibitors targeting p300, CBP, and specific deubiquitinase enzymes, which play a crucial role in regulating gene expression in cancer cells. Its primary research program addresses prostate cancer, a significant cause of male mortality, by modulating the androgen receptor pathway and potentially overcoming resistance mechanisms found in existing treatments. Additionally, CellCentric's products have applications in treating other cancers, including non-small cell lung cancer, breast cancer, and colon cancer. The company's approach aims to provide targeted therapies for various malignancies, addressing unmet medical needs in the oncology field.

Alpheus Medical develops a sonodynamic therapy platform for solid tumors, combining a drug with a device activated by ultrasound to deliver targeted treatment for recurrent glioblastoma multiforme and other cancers. The non-invasive outpatient approach aims to avoid imaging and hospital admission while concentrating therapy on malignant tissues.

TailorMed Medical Ltd., established in 2017 and based in Tel Aviv, Israel, specializes in health IT solutions. The company develops and provides financial navigation technology and systems, designed to streamline and automate financial processes for both patients and healthcare providers. Their offerings include TailorMed Financial Navigation, a platform to manage and automate financial processes; TailorMed Financial Insights, an analytics and reporting dashboard to track and measure key performance indicators; and TailorMed Pharmacy, a platform to simplify drug ordering, tracking, and billing based on patient treatment regimens.

Auron Therapeutics is a biotechnology company focused on cancer therapy development that seeks to change the paradigm from tumor cell killing to differentiation therapy, aiming to transform malignant cells into normal functioning cells by reactivating endogenous cellular programs. The company uses platforms that integrate large-omic datasets and miniaturized high-throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. This approach is designed to advance therapeutic candidates for cancer across areas of unmet medical need and to support the development of transformative medicines. Auron Therapeutics was founded in 2018 and is based in Wellesley, Massachusetts.

Tmunity Therapeutics, Inc. is a biotherapeutics company based in Philadelphia, Pennsylvania, that specializes in the development of innovative immunotherapies for cancer, infectious diseases, and autoimmune disorders. Founded in 2015, Tmunity focuses on harnessing the potential of T cells through novel technologies, including T Cell Receptor (TCR) engineered T cells and regulatory T cells (Treg). The company has developed advanced platforms that allow for precise control over T cell activation and direction in vivo, as well as proprietary methods for activating, expanding, and genetically engineering T cells sourced from peripheral blood, cord blood, and tumors. Tmunity aims to advance personalized next-generation immunotherapies and has a team of experts with extensive experience in T-cell biology and clinical development, enhancing its capability to conduct safe and effective clinical trials. Its robust manufacturing platform supports multi-center clinical studies across various therapeutic areas, positioning Tmunity at the forefront of immunotherapy innovation.

Navigating Cancer, Inc., established in 2008 and headquartered in Seattle, Washington, operates a Web-based patient care portal designed specifically for cancer programs. This platform enables cancer survivors to receive, organize, and understand their medical information, track their health, and engage with healthcare professionals. It also offers educational resources on various types of cancer and chemotherapy treatments. The portal aims to simplify practice workflows for healthcare providers, facilitate patient-centered care, and improve overall outcomes by empowering patients through technology.

Castle Biosciences is a molecular diagnostics company headquartered in Friendswood, Texas, that develops and commercializes gene‑expression‑profile tests for dermatologic cancers, uveal melanoma, and Barrett’s esophagus. Its flagship product, DecisionDx‑Melanoma, predicts the risk of metastasis in stage I and II cutaneous melanoma by analyzing 31 tumor‑derived genes. The company also offers DecisionDx‑UM for uveal melanoma, DecisionDx‑SCC for cutaneous squamous cell carcinoma, MyPath Melanoma for diagnostically challenging melanocytic lesions, and TissueCypher for predicting progression of high‑grade dysplasia in Barrett’s esophagus. Tests are delivered to physicians, physician assistants, and nurse practitioners to support personalized treatment decisions. Founded in 2007, Castle Biosciences focuses on providing clinically actionable genomic information to improve cancer diagnosis and management.

Alpheus Medical develops a sonodynamic therapy platform for solid tumors, combining a drug with a device activated by ultrasound to deliver targeted treatment for recurrent glioblastoma multiforme and other cancers. The non-invasive outpatient approach aims to avoid imaging and hospital admission while concentrating therapy on malignant tissues.